OncoAlert

Dear Colleagues, Presenting another great @GuardConsortium Educational Capsule. This month we have our friend @Ecastromarcos of Hospital 12 de Octubre in Madrid🇪🇸talking about the Changes in the Management of Metastatic Hormone Sensitive #ProstateCancer cc: @cdanicas @dralvaropinto @drenriquegrande @nachoduranm @DrJaVallejo @abraocantoMD @docjavip @AlvarezMa89031 @DrFelixGuerrero @BerUrologia @AnaPlatabello1 @scocmem @OncBrothers @Helena_de_Palma @F_lopez_campos @mjuanfi81 @EurUrolOncol Pinging OncoAlert Faculty @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin #OncoAlertAF @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem @AmandaNizamMD

What an honour to be introduced by three Presidents for the joint ESMO–ESTRO symposium on combining radiation and systemic therapy at #ESTRO26 A true reflection of how #multidisciplinary collaboration is shaping the future of #oncology #OncoAlert @OncoAlert @myESMO @ESTRO_RT

“Unlike the surgical incision, modeling tissue damage from radiotherapy is more complex” #ESTRO26 @OcathailS 1/

“For (almost) all!” @PBlanchardMD arguing in favor of treating the primary in both low and high volume disease! #ESTRO26

OncoAlert 🚨is Proud to partner with @ESTRO_RT 🌐and support the global radiation oncology community at #ESTRO26 ‼️ In this opening interview, ESTRO President Matthias Guckenberger 🇨🇭shares the vision behind this year’s theme, “Innovating Radiation Oncology, Together,” and what collaboration and innovation mean in practice for the future of #RadOnc ☢️ @Mat_Guc #RadOnc @yasemin09896924 @LindaMrissa @christian_roenn @Valeriadionisi @gerryhanna @clchiang_hk @mtugceyilmaz @B_Tomasik @gmpetrianni @CiroFranzese1 @Atem84 @piet_ost @brachyexpert @BlanceS90 @The_PT_Explorer @BarbaraJereczek @Mat_Guc @ZilliThomas @AnnaKirby17 @PBlanchardMD @achoud72 Pinging OA faculty @MKnoll_MD @_ShankarSiva @Icro_Meattini @seanmmcbride @NiuSanford @nataliagandur @acampsmalea @to_be_elizabeth

FDA Approval based on DESTINY-Breast11 and DESTINY-Breast05 in #BreastCancer buff.ly/ejhSvX9 The FDA approved fam-trastuzumab deruxtecan-nxki for two HER2-positive early-stage breast cancer indications: neoadjuvant therapy for Stage II/III disease followed by THP, and adjuvant treatment for patients with residual invasive disease after neoadjuvant HER2-targeted therapy. Approval was supported by DESTINY-Breast11 and DESTINY-Breast05, where T-DXd significantly improved pathologic complete response and invasive disease-free survival compared with standard HER2-directed regimens. Companion HER2 diagnostic assays were also approved. @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @nataliagandur @acampsmalea @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @Onco_Cifu88

💥NEOSUMMIT-01 trial in LA gastric/GEJ cancer: perioperative toripalimab + ChT vs ChT alone (3-year follow-up, n=108) ascopubs.org/doi/full/10.12… ▪️ 3-year EFS: 74.7% vs 56.2% (HR 0.51) ▪️ 3-year OS: 81.3% vs 72.2% (HR 0.45) ▪️ Benefit maintained across most predefined subgroups Perioperative IO TORI-pal the survival curves in GC 🍜 @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoTTD

It is the year of the Patient’s Voice! #ESTRO26

Nearly time to chair the debate. Come along to K1 at 8.45 and vote for brachytherapy. I have a feeling @Bach_Surgeon is going to give a compelling counter argument! #ESTRO26 #thisisbrachytherapy

📌 #RadOnc community, are you attending #ESTRO26 and would like a tailored journey focusing on spatially fractionated #radiotherapy (#SFRT)? From #Radiobiology, #MedPhys to #clinical, here you will find presentions on SFRT every day and a meet&greet session on Sunday! @ESTRO_RT

Keep up to date with the ESGO eAcademy! This month, in honor of World Ovarian Cancer Day, our eAcademy editors recommend viewing Ane Gerda Zahl Eriksson’s video “Surgical Procedures in Advanced Ovarian Cancer”.  That’s just one of many webinar recordings, surgical videos and more educational items about ovarian cancer on our knowledge portal. Explore it this weekend 👉 eacademy.esgo.org

JUST IN: @FDA approves Neoadjuvant Trastuzumab deruxtecan (TdXD) for Her-2 + breast cancer and post residual disease , based upon Destiny breast 011/05 trials. fda.gov/drugs/resource…

For those that couldnt make it to #AUA26, especially those at #ESTRO26, here were some of the slides for the "Pro" RT to primary in M1a disease. @TylerSbrt @UroCancer @CaPsurvivorship @PCaParker @Prof_Nick_James @wandering_gu

1/ 🧵 ANDROMEDA final analysis is practice-changing for newly diagnosed AL amyloidosis. IMPORTANT tweets: 3/4 and 6 for clinicians who treats Amyloidosis D-VCd = daratumumab + bortezomib/cyclophosphamide/dexamethasone. With 61.4 months median follow-up, D-VCd improved depth of response, organ recovery, MOD-PFS, and OS. 🔥 #USMIRC #MedEd #medtwitter #mmsm #myeloma @USMIRCNEWS @US_HMC @MedwatchKate @Larvol @OncoAlert

Wow- big month for breast approvals so far...and it's only May 15th! #TDXd approved for neoadjuvant and adjuvant HER-2+ #bcsm Our @US_FDA breast colleagues have been very busy, thank you!

To help stop cancer misinformation on social media, healthcare providers can participate in social networks to see the types of content to which their patients are exposed, disseminate evidence‐based information, and correct misinformation. acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… @LoebStacy

1L Melanoma PD1 vs PD1+LAG3 from @Regeneron is (-) —another setback for the IO/ICI field. We keep pressing. Some interesting trends and signals @OncoAlert @sitcancer @OncBrothers investor.regeneron.com/news-releases/…

🧬 Liquid biopsy can now profile the tumor microenvironment (TME) • 🧪 Deep-learning analysis of cfDNA methylation profiles inferred spatial TME ecosystems directly from plasma • 🌐 Plasma-derived “liquid ecotypes” captured distinct immune/stromal ecosystems linked to geography within tumors (margin vs core) • 🎯 Liquid TME profiling predicted ICB response: immune-active SE7/SE8 → benefit; stromal/hypoxic SE4 → resistance • 📊 In melanoma, liquid ecotypes showed stronger survival associations than PD-L1 or TMB in several analyses • 🔄 This enables a new paradigm: serial, non-invasive monitoring of the evolving TME ecosystem during therapy nature.com/articles/s4158… #LiquidBiopsy #PrecisionOncology

Thank you Governor @maura_healey for visiting @DanaFarber, meeting us all and listening to @CJSTRAV3 (stage IV Kidney Cancer) how burdensome, time-consuming and stressful prior authorizations are! Eliminating them in @MassGov Commonwealth is a big win for everyone!

Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70): Protocol for a hybrid implementation-effectiveness study in three community oncology practices in the United States geriatriconcology.net/article/S1879-… @WilliamDale_MD @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Elsevier #GeriatricAssessment #ToleranceofTreatment

🚨 THE 15 MOST IMPORTANT TRIALS OF #ASCO26 May 29 - June 2 | Chicago Which trial are you watching most closely? 🌟 PLENARY GAME-CHANGERS 1️⃣ PROTEUS Perioperative apalutamide + ADT in high-risk localized prostate cancer 2️⃣ LIBRETTO-432 Adjuvant selpercatinib in RET+ NSCLC 3️⃣ HARMONi-6 Ivonescimab + chemo vs tislelizumab + chemo in squamous NSCLC 4️⃣ RASolute 302 Daraxonrasib (RMC-6236) in metastatic pancreatic cancer 5️⃣ SARC041 Abemaciclib in dedifferentiated liposarcoma ⚡ FRONTLINE & PERIOPERATIVE SHIFTS 6️⃣ KEYNOTE-B15 / EV-304 EV + pembrolizumab vs chemo in MIBC 7️⃣ LITESPARK-022 Pembrolizumab + belzutifan in adjuvant ccRCC 8️⃣ AMBITION Paclitaxel/bevacizumab ± atezolizumab in HR+ breast cancer 9️⃣ NeoADAURA Neoadjuvant osimertinib in EGFR+ NSCLC 🔟 A-DREAM ADT interruption strategies in mCSPC 🧬 PRECISION, ADCs & NEXT-GEN IMMUNOLOGY 1️⃣1️⃣ DESTINY-Breast06 T-DXd expands into HER2-ultralow disease 1️⃣2️⃣ CROWN (7-year update) Lorlatinib durability in ALK+ NSCLC 1️⃣3️⃣ DeLLphi-312 Tarlatamab in frontline SCLC 1️⃣4️⃣ COMMIT Atezolizumab + FOLFOX/Bev in MSI-H mCRC 1️⃣5️⃣ IMvigor011 ctDNA-guided adjuvant atezolizumab in bladder cancer #OncoTwitter #MedTwitter #ASCO26 #CancerResearch @OncoAlert @ASCO @JCOPO_ASCO @OncBrothers